BioLargo’s Recent Corporate Updates Reinforce Investor Confidence
BioLargo, Inc. (OTCQX: BLGO) continues to build momentum, with its recent quarterly and year-over-year (YoY) financial updates in early August 2024. BioLargo release shows consistent growth across all divisions. The company’s innovative AEC PFAS elimination technology has attracted increased attention, positioning BioLargo as a leader in cleantech solutions and driving investor confidence. The company’s AEC PFAS elimination technology has garnered extensive analysis at TradersQue over the past year, including our podcast coverage.
BioLargo Inc Stock Price Today | OTC BLGO Live Ticker – Investing.com
Q2 2024 Financial Summary
Key Highlights
Record Revenue: $5.0 million for the quarter, marking a 247% increase YoY and 5% increase QoQ. Year-to-date (YTD) revenues totaled $9.773 million, reflecting an 88% increase over the same period in 2023. BioLargo produced $4.8 million in cash and cash equivalents, with total assets equaling $10.1 million as of June 30, 2024. The company’s current annual revenue run rate stands at $19.5 million.
Net Loss: $780,000 for the quarter, including $669,000 (85%) in non-cash equity compensation. Data remained flat compared to the prior quarter.
Total Stockholders’ Equity: Increased to $5.9 million as of June 30, 2024, a 64% increase compared to $3.6 million in June 2023, and up 9% from $5.4 million at the end of the previous quarter.
The continued financial strength of BioLargo, Inc. signals near- and long-term growth and value for the company as it evolves its various business divisions and respective cleantech products and services.
Recent Stock Offerings Status
Three separate prospectuses were published in late April detailing stock offerings by BioLargo, Inc., involving shares to be sold by selling stockholders and potential proceeds from the exercise of outstanding warrants and purchase agreements. As of mid-September 2024, each of these offerings remain active. These include two warrant exercises and a purchase agreement with Lincoln Park. The first two offerings could generate up to $4.48 million and $9.02 million, respectively, if all warrants are exercised. The Lincoln Park agreement has already raised $923,420, with potential for up to $9.08 million in future proceeds. These funds are allocated for working capital, debt repayment, and research and development.
Industrial AEC Pilot Project Status
In December 2023, BioLargo’s Aqueous Electrostatic Concentrator (AEC) technology was selected for installation at a drinking water treatment facility in Stockholm, New Jersey, marking a significant step forward for the company’s PFAS removal solution. To date, BioLargo remains the exclusive global leader in PFAS removal using non-ion-exchange, non-carbon-based alternative technology at a commercial or industrial scale.
The AEC unit for Lake Stockholm Systems, Inc., is presently ready for installation, with operations to commence by or before November 2024. This represents BioLargo’s first industrial-scale project and a significant milestone for the company, who will assuredly receive similar contracts as PFAS removal requirements expand courtesy of emerging EPA policies and at the behest of U.S. state and local governments seeking remediation from manufacturers of PFAS chemicals despite their known dangers.
PFAS Revisited
The inclusion of PFAS in industrial and commercial goods boasting to be “stick”-proof, waterproof, to fire-resistant proved financially lucrative to manufacturers, but that has now proven cost-prohibitive to those same corporations as they find themselves increasingly in the crosshairs of civil suits brought forth by often a tandem of government agencies, private citizens, and even other businesses operating on contaminated land, notably dumpsites, held priorly by PFAS producers but that are now liable to fund proper handling and disposal methods.
The chosen PFAS-removal method–granular activated carbon (BAC), ion-exchange, or AEC–ultimately dictates handling and disposal costs, which can comprise easily the majority of a tight budget. And although upfront operational costs are more affordable for users of GAC, the subsequent handling and removal of tens of thousands of pounds of PFAS-laden waste will prove financially ruinous when compared to BioLargo’s AEC method–one that can super-concentrate thousands of metric tons of waste into single-digit pounds and for a cost that is mere pennies-on-the-dollar.
EPA Accelerates PFAS Roadmap; BioLargo, Inc. to Benefit – TradersQue.com
Effects of the Chevron Deference Overruling
In June 2024, the Supreme Court overturned *Chevron* deference, limiting the power of federal agencies like the EPA to interpret ambiguous laws. The Chevron deference originated from the 1984 Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. case, where the Supreme Court ruled that courts should defer to federal agencies’ interpretations of ambiguous statutes, provided the interpretation is reasonable.
The overturning of this prior precedent could have significant ramifications for the EPA’s roadmap to eliminate PFAS, as courts will now more closely scrutinize the agency’s regulatory actions. Challenges to PFAS regulations, such as maximum contaminant levels and hazardous substance designations, may become more difficult for the EPA to defend, potentially delaying or weakening enforcement efforts to address these harmful chemicals.
However, the overturning of Chevron deference is unlikely to significantly affect EPA policies on PFAS remediation because much of the EPA’s authority to regulate hazardous substances like PFAS stems from clearly defined statutes, such as the Clean Water Act and the Safe Drinking Water Act. These laws provide explicit mandates for the EPA, reducing the need for judicial deference to agency interpretation in this context. Moreover, the tens of billions of dollars willfully established to national cleanup efforts by previous PFAS producers 3M and DuPont, among others, ensure the likely survival of future PFAS legislation through such scrutiny. Any judicial proceedings will invariably be settled on a state-by-state, case-by-case basis and may focus predominantly on costs of compliance and resource allocation (i.e., required specialized equipment).
About BioLargo, Inc.
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The company’s core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. BioLargo’s approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
Previous Coverage
Please review our archives for past coverage on BioLargo, Inc. TradersQue.com remains loyal to and confident of BioLargo, Inc.’s near-term future and long-term future across all business divisions, products, and services. Government contracts for PFAS-removal projects are inevitable as the EPA’s new requirements represent the first set of federally based policies over drinking water quality that, previously, individual states directed. The tens of billions of dollars in current and inevitable funding, in addition to EPS-based infrastructural support–will deliver to BioLargo a number of projects of varying scale and scope as to position the company well head of its competition and peers.
Additional coverage can be found via Todd Analytics’ X and LinkedIn social media accounts.
